{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:29:26Z","timestamp":1791916166474,"version":"4.3.4"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001736","name":"German-Israeli Foundation for Scientific Research and Development","doi-asserted-by":"publisher","award":["I-65-412.20-2016"],"award-info":[{"award-number":["I-65-412.20-2016"]}],"id":[{"id":"10.13039\/501100001736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB-1399"],"award-info":[{"award-number":["SFB-1399"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["A01\/C02"],"award-info":[{"award-number":["A01\/C02"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KFO-286-RP2"],"award-info":[{"award-number":["KFO-286-RP2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RE 2246\/13-1"],"award-info":[{"award-number":["RE 2246\/13-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["R12\/08"],"award-info":[{"award-number":["R12\/08"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["EKFS-2014-A06"],"award-info":[{"award-number":["EKFS-2014-A06"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2016_Kolleg.19"],"award-info":[{"award-number":["2016_Kolleg.19"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["1117240"],"award-info":[{"award-number":["1117240"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113041"],"award-info":[{"award-number":["70113041"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113307"],"award-info":[{"award-number":["70113307"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["BMBF e:Med 01ZX1303A"],"award-info":[{"award-number":["BMBF e:Med 01ZX1303A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008001","name":"Universit\u00e4t zu K\u00f6ln","doi-asserted-by":"publisher","award":["Gerok rotation position"],"award-info":[{"award-number":["Gerok rotation position"]}],"id":[{"id":"10.13039\/501100008001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008001","name":"Universit\u00e4t zu K\u00f6ln","doi-asserted-by":"publisher","award":["K\u00f6ln Fortune position"],"award-info":[{"award-number":["K\u00f6ln Fortune position"]}],"id":[{"id":"10.13039\/501100008001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["NKI 2015-7877"],"award-info":[{"award-number":["NKI 2015-7877"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R223-2016-956"],"award-info":[{"award-number":["R223-2016-956"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["NWO Vici project 91814643"],"award-info":[{"award-number":["NWO Vici project 91814643"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["NWO Mosaic program grant 017.008.022"],"award-info":[{"award-number":["NWO Mosaic program grant 017.008.022"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The majority of <jats:italic>BRCA1<\/jats:italic>-mutant breast cancers are characterized by a triple-negative phenotype and a basal-like molecular subtype, associated with aggressive clinical behavior. Current treatment options are limited, highlighting the need for the development of novel targeted therapies for this tumor subtype.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Our group previously showed that EZH2 is functionally relevant in BRCA1-deficient breast tumors and blocking EZH2 enzymatic activity could be a potent treatment strategy. To validate the role of EZH2 as a therapeutic target and to identify new synergistic drug combinations, we performed a high-throughput drug combination screen in various cell lines derived from BRCA1-deficient and -proficient mouse mammary tumors.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified the combined inhibition of EZH2 and the proximal DNA damage response kinase ATM as a novel synthetic lethality-based therapy for the treatment of BRCA1-deficient breast tumors. We show that the combined treatment with the EZH2 inhibitor GSK126 and the ATM inhibitor AZD1390 led to reduced colony formation, increased genotoxic stress, and apoptosis-mediated cell death in BRCA1-deficient mammary tumor cells in vitro. These findings were corroborated by in vivo experiments showing that simultaneous inhibition of EZH2 and ATM significantly increased anti-tumor activity in mice bearing BRCA1-deficient mammary tumors.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Taken together, we identified a synthetic lethal interaction between EZH2 and ATM and propose this synergistic interaction as a novel molecular combination for the treatment of <jats:italic>BRCA1<\/jats:italic>-mutant breast cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-022-01534-y","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T18:02:41Z","timestamp":1655488961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4783-987X","authenticated-orcid":false,"given":"Leonie","family":"Ratz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Brambillasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandra","family":"Bartke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim A.","family":"Huetzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Goergens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsolya","family":"Leidecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron D.","family":"Jachimowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Proost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Siteur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"de Korte-Grimmerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bouwman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia M.","family":"Pulver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roebi","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Isensee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hucho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"van Lohuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mallmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Jonkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Puppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"issue":"14","key":"1534_CR1","doi-asserted-by":"publisher","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1534_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","volume":"21","author":"N Mavaddat","year":"2012","unstructured":"Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA). Cancer Epidemiol Biomark Prev. 2012;21(1):134\u201347.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"15","key":"1534_CR3","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764\u201373.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1534_CR4","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A. Hallmarks of \u201cBRCAness\u201d in sporadic cancers. Nat Rev Cancer. 2004;4(10):814\u20139.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1534_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628\u201337.","journal-title":"Nat Med"},{"issue":"7","key":"1534_CR6","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","volume":"29","author":"F Poggio","year":"2018","unstructured":"Poggio F, Bruzzone M, Ceppi M, Ponde NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7):1497\u2013508.","journal-title":"Ann Oncol"},{"issue":"12","key":"1534_CR7","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","volume":"29","author":"S Loibl","year":"2018","unstructured":"Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, et al. Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018;29(12):2341\u20137.","journal-title":"Ann Oncol"},{"issue":"10","key":"1534_CR8","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","volume":"3","author":"E Hahnen","year":"2017","unstructured":"Hahnen E, Lederer B, Hauke J, Loibl S, Krober S, Schneeweiss A, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 2017;3(10):1378\u201385.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1534_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"WM Sikov","year":"2015","unstructured":"Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13\u201321.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1534_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","volume":"108","author":"AR Venkitaraman","year":"2002","unstructured":"Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171\u201382.","journal-title":"Cell"},{"issue":"4","key":"1534_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1023\/A:1018792200700","volume":"3","author":"R Hakem","year":"1998","unstructured":"Hakem R, de la Pompa JL, Mak TW. Developmental studies of Brca1 and Brca2 knock-out mice. J Mammary Gland Biol Neoplasia. 1998;3(4):431\u201345.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"6","key":"1534_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333.","journal-title":"N Engl J Med"},{"issue":"10","key":"1534_CR13","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","volume":"29","author":"SM Noordermeer","year":"2019","unstructured":"Noordermeer SM, van Attikum H. PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. Trends Cell Biol. 2019;29(10):820\u201334.","journal-title":"Trends Cell Biol"},{"issue":"14","key":"1534_CR14","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1158\/1078-0432.CCR-18-4024","volume":"25","author":"J Puppe","year":"2019","unstructured":"Puppe J, Opdam M, Schouten PC, Jozwiak K, Lips E, Severson T, et al. EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy. Clin Cancer Res. 2019;25(14):4351\u201362.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1534_CR15","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/emboj.2013.95","volume":"32","author":"L Wang","year":"2013","unstructured":"Wang L, Zeng X, Chen S, Ding L, Zhong J, Zhao JC, et al. BRCA1 is a negative modulator of the PRC2 complex. EMBO J. 2013;32(11):1584\u201397.","journal-title":"EMBO J"},{"issue":"7291","key":"1534_CR16","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08975","volume":"464","author":"RA Gupta","year":"2010","unstructured":"Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071\u20136.","journal-title":"Nature"},{"issue":"5595","key":"1534_CR17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1076997","volume":"298","author":"R Cao","year":"2002","unstructured":"Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298(5595):1039\u201343.","journal-title":"Science"},{"issue":"9","key":"1534_CR18","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-10-2156","volume":"17","author":"A Chase","year":"2011","unstructured":"Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011;17(9):2613\u20138.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1534_CR19","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/bcr2354","volume":"11","author":"J Puppe","year":"2009","unstructured":"Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, et al. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res. 2009;11(4):R63.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"1534_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.celrep.2019.12.056","volume":"30","author":"S Yomtoubian","year":"2020","unstructured":"Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, et al. Inhibition of EZH2 catalytic activity selectively targets a metastatic subpopulation in triple-negative breast cancer. Cell Rep. 2020;30(3):755-70.e6.","journal-title":"Cell Rep"},{"issue":"1","key":"1534_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13148-019-0734-x","volume":"11","author":"H Yang","year":"2019","unstructured":"Yang H, Cui W, Wang L. Epigenetic synthetic lethality approaches in cancer therapy. Clin Epigenetics. 2019;11(1):136.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"1534_CR22","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41467-018-04864-8","volume":"9","author":"A Hirukawa","year":"2018","unstructured":"Hirukawa A, Smith HW, Zuo D, Dufour CR, Savage P, Bertos N, et al. Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. Nat Commun. 2018;9(1):2547.","journal-title":"Nat Commun"},{"issue":"1","key":"1534_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2014-05-577270","volume":"125","author":"J Van der Meulen","year":"2015","unstructured":"Van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F, Matthijssens F, et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood. 2015;125(1):13\u201321.","journal-title":"Blood"},{"issue":"4","key":"1534_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","volume":"18","author":"BG Wilson","year":"2010","unstructured":"Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, et al. Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation. Cancer Cell. 2010;18(4):316\u201328.","journal-title":"Cancer Cell"},{"issue":"7546","key":"1534_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature14122","volume":"520","author":"CM Fillmore","year":"2015","unstructured":"Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature. 2015;520(7546):239\u201342.","journal-title":"Nature"},{"issue":"3","key":"1534_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nm.3799","volume":"21","author":"BG Bitler","year":"2015","unstructured":"Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015;21(3):231\u20138.","journal-title":"Nat Med"},{"key":"1534_CR27","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1634\/theoncologist.2019-0493","volume":"25","author":"SA Hurvitz","year":"2019","unstructured":"Hurvitz SA, Goncalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA trial. Oncologist. 2019;25:e439\u201350.","journal-title":"Oncologist"},{"issue":"26","key":"1534_CR28","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"5","key":"1534_CR29","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.cell.2007.02.025","volume":"128","author":"DP Silver","year":"2007","unstructured":"Silver DP, Dimitrov SD, Feunteun J, Gelman R, Drapkin R, Lu SD, et al. Further evidence for BRCA1 communication with the inactive X chromosome. Cell. 2007;128(5):991\u20131002.","journal-title":"Cell"},{"issue":"6","key":"1534_CR30","doi-asserted-by":"publisher","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","volume":"4","author":"ST Durant","year":"2018","unstructured":"Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018;4(6):eaat1719.","journal-title":"Sci Adv"},{"issue":"10","key":"1534_CR31","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1158\/1535-7163.MCT-09-0519","volume":"8","author":"SE Golding","year":"2009","unstructured":"Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009;8(10):2894\u2013902.","journal-title":"Mol Cancer Ther"},{"issue":"W1","key":"1534_CR32","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48(W1):W488\u201393.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"1534_CR33","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell. 2017;66(6):801\u201317.","journal-title":"Mol Cell"},{"issue":"8","key":"1534_CR34","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","volume":"15","author":"M Choi","year":"2016","unstructured":"Choi M, Kipps T, Kurzrock R. ATM mutations in cancer: therapeutic implications. Mol Cancer Ther. 2016;15(8):1781\u201391.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"1534_CR35","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1016\/j.drudis.2019.09.002","volume":"24","author":"AHC Vlot","year":"2019","unstructured":"Vlot AHC, Aniceto N, Menden MP, Ulrich-Merzenich G, Bender A. Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls. Drug Discov Today. 2019;24(12):2286\u201398.","journal-title":"Drug Discov Today"},{"key":"1534_CR36","doi-asserted-by":"publisher","first-page":"20864","DOI":"10.1038\/srep20864","volume":"6","author":"X Song","year":"2016","unstructured":"Song X, Gao T, Wang N, Feng Q, You X, Ye T, et al. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer. Sci Rep. 2016;6:20864.","journal-title":"Sci Rep"},{"issue":"47","key":"1534_CR37","doi-asserted-by":"publisher","first-page":"18507","DOI":"10.1073\/pnas.0806213105","volume":"105","author":"MJ Herold","year":"2008","unstructured":"Herold MJ, van den Brandt J, Seibler J, Reichardt HM. Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proc Natl Acad Sci U S A. 2008;105(47):18507\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1534_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-1-60327-409-8_18","volume":"682","author":"CE Redon","year":"2011","unstructured":"Redon CE, Nakamura AJ, Sordet O, Dickey JS, Gouliaeva K, Tabb B, et al. gamma-H2AX detection in peripheral blood lymphocytes, splenocytes, bone marrow, xenografts, and skin. Methods Mol Biol. 2011;682:249\u201370.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"1534_CR39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.cell.2018.11.024","volume":"176","author":"RD Jachimowicz","year":"2019","unstructured":"Jachimowicz RD, Beleggia F, Isensee J, Velpula BB, Goergens J, Bustos MA, et al. UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors. Cell. 2019;176(3):505-19.e22.","journal-title":"Cell"},{"issue":"12","key":"1534_CR40","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/ncb892","volume":"4","author":"RA DiTullio Jr","year":"2002","unstructured":"DiTullio RA Jr, Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J, et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol. 2002;4(12):998\u20131002.","journal-title":"Nat Cell Biol"},{"issue":"7427","key":"1534_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(7427):108\u201312.","journal-title":"Nature"},{"key":"1534_CR42","doi-asserted-by":"publisher","first-page":"8455","DOI":"10.2147\/OTT.S186498","volume":"11","author":"Y Yang","year":"2018","unstructured":"Yang Y, Zhu F, Wang Q, Ding Y, Ying R, Zeng L. Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells. Onco Targets Ther. 2018;11:8455\u201363.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"1534_CR43","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.18632\/oncotarget.13773","volume":"8","author":"D Zeng","year":"2017","unstructured":"Zeng D, Liu M, Pan J. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells. Oncotarget. 2017;8(2):3396\u2013411.","journal-title":"Oncotarget"},{"issue":"9","key":"1534_CR44","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.3390\/cancers12092541","volume":"12","author":"S Park","year":"2020","unstructured":"Park S, Jo SH, Kim JH, Kim SY, Ha JD, Hwang JY, et al. Combination treatment with GSK126 and pomalidomide induces B-cell differentiation in EZH2 gain-of-function mutant diffuse large B-cell lymphoma. Cancers (Basel). 2020;12(9):2541.","journal-title":"Cancers (Basel)."},{"key":"1534_CR45","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.2147\/OTT.S237474","volume":"13","author":"S Liu","year":"2020","unstructured":"Liu S, Rong G, Li X, Geng L, Zeng Z, Jiang D, et al. Diosgenin and GSK126 produce synergistic effects on epithelial\u2013mesenchymal transition in gastric cancer cells by mediating EZH2 via the Rho\/ROCK signaling pathway. Onco Targets Ther. 2020;13:5057\u201367.","journal-title":"Onco Targets Ther"},{"issue":"24","key":"1534_CR46","doi-asserted-by":"publisher","first-page":"9501","DOI":"10.3390\/ijms21249501","volume":"21","author":"J Wang","year":"2020","unstructured":"Wang J, Wang GG. No easy way out for EZH2: its pleiotropic, noncanonical effects on gene regulation and cellular function. Int J Mol Sci. 2020;21(24):9501.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1534_CR47","first-page":"4249","volume":"19","author":"L Xu","year":"2019","unstructured":"Xu L, Tang H, Wang K, Zheng Y, Feng J, Dong H, et al. Pharmacological inhibition of EZH2 combined with DNAdamaging agents interferes with the DNA damage response in MM cells. Mol Med Rep. 2019;19(5):4249\u201355.","journal-title":"Mol Med Rep"},{"issue":"43","key":"1534_CR48","doi-asserted-by":"publisher","first-page":"18475","DOI":"10.1073\/pnas.1012946107","volume":"107","author":"DM Chou","year":"2010","unstructured":"Chou DM, Adamson B, Dephoure NE, Tan X, Nottke AC, Hurov KE, et al. A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc Natl Acad Sci U S A. 2010;107(43):18475\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1534_CR49","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.molcel.2014.06.028","volume":"55","author":"A Kakarougkas","year":"2014","unstructured":"Kakarougkas A, Ismail A, Chambers AL, Riballo E, Herbert AD, Kunzel J, et al. Requirement for PBAF in transcriptional repression and repair at DNA breaks in actively transcribed regions of chromatin. Mol Cell. 2014;55(5):723\u201332.","journal-title":"Mol Cell"},{"issue":"7","key":"1534_CR50","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-19-0789","volume":"10","author":"TE Leon","year":"2020","unstructured":"Leon TE, Rapoz-D\u2019Silva T, Bertoli C, Rahman S, Magnussen M, Philip B, et al. EZH2-deficient T-cell acute lymphoblastic leukemia is sensitized to CHK1 inhibition through enhanced replication stress. Cancer Discov. 2020;10(7):998\u20131017.","journal-title":"Cancer Discov"},{"issue":"13","key":"1534_CR51","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1016\/j.celrep.2018.03.002","volume":"22","author":"T Ito","year":"2018","unstructured":"Ito T, Teo YV, Evans SA, Neretti N, Sedivy JM. Regulation of cellular senescence by polycomb chromatin modifiers through distinct DNA damage- and histone methylation-dependent pathways. Cell Rep. 2018;22(13):3480\u201392.","journal-title":"Cell Rep"},{"issue":"13","key":"1534_CR52","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1073\/pnas.1719532115","volume":"115","author":"G Kuser-Abali","year":"2018","unstructured":"Kuser-Abali G, Gong L, Yan J, Liu Q, Zeng W, Williamson A, et al. An EZH2-mediated epigenetic mechanism behind p53-dependent tissue sensitivity to DNA damage. Proc Natl Acad Sci U S A. 2018;115(13):3452\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"1534_CR53","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1593\/neo.05472","volume":"7","author":"M Zeidler","year":"2005","unstructured":"Zeidler M, Varambally S, Cao Q, Chinnaiyan AM, Ferguson DO, Merajver SD, et al. The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia. 2005;7(11):1011\u20139.","journal-title":"Neoplasia"},{"issue":"29","key":"1534_CR54","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1073\/pnas.1706392114","volume":"114","author":"CC Chen","year":"2017","unstructured":"Chen CC, Kass EM, Yen WF, Ludwig T, Moynahan ME, Chaudhuri J, et al. ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair. Proc Natl Acad Sci U S A. 2017;114(29):7665\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1534_CR55","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/sj.emboj.7601115","volume":"25","author":"L Cao","year":"2006","unstructured":"Cao L, Kim S, Xiao C, Wang RH, Coumoul X, Wang X, et al. ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. EMBO J. 2006;25(10):2167\u201377.","journal-title":"EMBO J"},{"issue":"2","key":"1534_CR56","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1158\/1541-7786.MCR-19-0141","volume":"18","author":"J Naskou","year":"2020","unstructured":"Naskou J, Beiter Y, van Rensburg R, Honisch E, Rudelius M, Schlensog M, et al. EZH2 loss drives resistance to carboplatin and paclitaxel in serous ovarian cancers expressing ATM. Mol Cancer Res. 2020;18(2):278\u201386.","journal-title":"Mol Cancer Res"},{"issue":"11","key":"1534_CR57","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.chembiol.2014.09.017","volume":"21","author":"WD Bradley","year":"2014","unstructured":"Bradley WD, Arora S, Busby J, Balasubramanian S, Gehling VS, Nasveschuk CG, et al. EZH2 inhibitor efficacy in non-Hodgkin\u2019s lymphoma does not require suppression of H3K27 monomethylation. Chem Biol. 2014;21(11):1463\u201375.","journal-title":"Chem Biol"},{"issue":"12","key":"1534_CR58","doi-asserted-by":"publisher","first-page":"e111840","DOI":"10.1371\/journal.pone.0111840","volume":"9","author":"SK Knutson","year":"2014","unstructured":"Knutson SK, Warholic NM, Johnston LD, Klaus CR, Wigle TJ, Iwanowicz D, et al. Synergistic anti-tumor activity of EZH2 inhibitors and glucocorticoid receptor agonists in models of germinal center non-Hodgkin lymphomas. PLoS ONE. 2014;9(12):e111840.","journal-title":"PLoS ONE"},{"issue":"6","key":"1534_CR59","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920\u20138.","journal-title":"Nat Med"},{"issue":"14","key":"1534_CR60","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1158\/1078-0432.CCR-18-0468","volume":"25","author":"AA Kraya","year":"2019","unstructured":"Kraya AA, Maxwell KN, Wubbenhorst B, Wenz BM, Pluta J, Rech AJ, et al. Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer. Clin Cancer Res. 2019;25(14):4363\u201374.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1534_CR61","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675\u20138.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1534_CR62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics"},{"issue":"7","key":"1534_CR63","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923\u201330.","journal-title":"Bioinformatics"},{"issue":"10","key":"1534_CR64","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Anders","year":"2010","unstructured":"Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11(10):R106.","journal-title":"Genome Biol"},{"issue":"3","key":"1534_CR65","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss CI. THE TOXICITY OF POISONS APPLIED JOINTLY1. Ann Appl Biol. 1939;26(3):585\u2013615.","journal-title":"Ann Appl Biol"},{"issue":"19","key":"1534_CR66","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1158\/0008-5472.CAN-18-3959","volume":"79","author":"J Erber","year":"2019","unstructured":"Erber J, Steiner JD, Isensee J, Lobbes LA, Toschka A, Beleggia F, et al. Dual inhibition of GLUT1 and the ATR\/CHK1 kinase axis displays synergistic cytotoxicity in KRAS-mutant cancer cells. Cancer Res. 2019;79(19):4855\u201368.","journal-title":"Cancer Res"},{"key":"1534_CR67","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1748-717X-2-4","volume":"2","author":"M Niyazi","year":"2007","unstructured":"Niyazi M, Niyazi I, Belka C. Counting colonies of clonogenic assays by using densitometric software. Radiat Oncol. 2007;2:4.","journal-title":"Radiat Oncol"},{"issue":"4","key":"1534_CR68","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/ng747","volume":"29","author":"J Jonkers","year":"2001","unstructured":"Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001;29(4):418\u201325.","journal-title":"Nat Genet"},{"issue":"29","key":"1534_CR69","doi-asserted-by":"publisher","first-page":"12111","DOI":"10.1073\/pnas.0702969104","volume":"104","author":"X Liu","year":"2007","unstructured":"Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A. 2007;104(29):12111\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"44","key":"1534_CR70","doi-asserted-by":"publisher","first-page":"17079","DOI":"10.1073\/pnas.0806092105","volume":"105","author":"S Rottenberg","year":"2008","unstructured":"Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105(44):17079\u201384.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-022-01534-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-022-01534-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-022-01534-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T19:09:28Z","timestamp":1655492968000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-022-01534-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1186\/s13058-022-01534-y","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"2 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is compliant with all relevant ethical regulations regarding animal research. All animal experiments were approved by the Animal Ethics Committee of The Netherlands Cancer Institute (Amsterdam, the Netherlands) and performed in accordance with the Dutch Act on Animal Experimentation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors revised and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.C.R. received consulting and lecture fees from Abbvie, AstraZeneca, Vertex and Merck. H.C.R. received research funding from Gilead Pharmaceuticals. H.C.R. is a co-founder of CDL Therapeutics GmbH. The remaining authors declare no competing financial interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}